BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 37528334)

  • 21. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
    Kameda R; Ando T; Kobayashi S; Ueno M; Ohkawa S
    Jpn J Clin Oncol; 2013 Jun; 43(6):636-40. PubMed ID: 23619988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
    Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
    Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
    Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant Chemotherapy and Outcomes in Older Adult Patients With Biliary Tract Cancer.
    Gbolahan OB; Zhi X; Liu Y; Shah MM; Kooby DA; Alese OB
    JAMA Netw Open; 2024 Jan; 7(1):e2351502. PubMed ID: 38206623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
    Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
    Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
    Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
    BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
    Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
    Choi IS; Kim KH; Lee JH; Suh KJ; Kim JW; Park JH; Kim YJ; Kim JS; Kim JH; Kim JW
    Eur J Cancer; 2021 Sep; 154():288-295. PubMed ID: 34303267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world treatment outcomes of metastatic biliary tract cancer patients in Japan: the Tokushukai REAl-world data project 04 (TREAD 04).
    Shimoyama R; Imamura Y; Uryu K; Mase T; Taguri M; Okuda T; Fujimura Y; Hayashi M; Tanaka S; Sawamukai K; Minami H
    Jpn J Clin Oncol; 2024 Jan; 54(1):70-80. PubMed ID: 37801431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
    BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
    Kim BJ; Yoo C; Kim KP; Hyung J; Park SJ; Ryoo BY; Chang HM
    Br J Cancer; 2017 Feb; 116(5):561-567. PubMed ID: 28081540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer.
    Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Sasahira N; Hirano K; Tsujino T; Tada M; Omata M; Koike K
    Invest New Drugs; 2011 Dec; 29(6):1488-93. PubMed ID: 20607585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis.
    Ji JH; Kim YS; Park I; Lee SI; Kim RB; Park JO; Oh SY; Hwang IG; Jang JS; Song HN; Kang JH
    Cancer Res Treat; 2018 Jul; 50(3):791-800. PubMed ID: 28838033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer.
    Yokoyama T; Yoshida H; Makino H; Maruyama H; Suzuki S; Matsutani T; Matsushita A; Hirakata A; Sasajima K; Uchida E
    J Nippon Med Sch; 2012; 79(3):204-12. PubMed ID: 22791122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy with gemcitabine plus cisplatin in patients with advanced biliary tract carcinoma at Chang Gung Memorial Hospital: a retrospective analysis.
    Wu CE; Hsu HC; Shen WC; Lin YC; Wang HM; Chang JW; Chen JS
    Chang Gung Med J; 2012; 35(5):420-7. PubMed ID: 23127347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study).
    Okano N; Furuse J; Ueno M; Morizane C; Yamanaka T; Ojima H; Ozaka M; Sasaki M; Takahara N; Nakai Y; Kobayashi S; Morimoto M; Hosoi H; Maeno S; Nagashima F; Ikeda M; Okusaka T
    Oncologist; 2021 Feb; 26(2):97-e201. PubMed ID: 33010112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of biliary drainage on chemotherapy in patients with biliary tract cancer: an exploratory analysis of the BT22 study.
    Fukutomi A; Furuse J; Okusaka T; Miyazaki M; Taketsuna M; Koshiji M; Nimura Y
    HPB (Oxford); 2012 Apr; 14(4):221-7. PubMed ID: 22404259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.
    Chung MJ; Kim YJ; Park JY; Bang S; Song SY; Chung JB; Park SW
    Chemotherapy; 2011; 57(3):236-43. PubMed ID: 21597288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.
    Okusaka T; Nakachi K; Fukutomi A; Mizuno N; Ohkawa S; Funakoshi A; Nagino M; Kondo S; Nagaoka S; Funai J; Koshiji M; Nambu Y; Furuse J; Miyazaki M; Nimura Y
    Br J Cancer; 2010 Aug; 103(4):469-74. PubMed ID: 20628385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients.
    Okamoto T; Takeda T; Sasaki T; Hamada T; Mie T; Ishitsuka T; Yamada M; Nakagawa H; Hirai T; Furukawa T; Kasuga A; Ozaka M; Sasahira N
    Curr Oncol; 2023 Jul; 30(8):7229-7240. PubMed ID: 37623005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.